Siteman Cancer Center earns highest NCI rating

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis received an “exceptional” rating from NCI during its site visit for 2020.

The evaluation resulted in a nearly perfect score from NCI.

Siteman earned its latest exceptional rating based on a January site visit by 22 researchers and administrators from academic cancer centers across the U.S. During the visit, Washington University researchers and physicians presented research programs that included:

  • Siteman’s portfolio of more than 600 clinical studies and the cancer center’s enrollment of more than 12,000 patients in clinical studies per year.

  • Genomic research to identify personalized targets and create personalized vaccines.

  • The use of ultrasound and photoacoustic imaging, which relies on light and sound rather than tissue samples, to diagnose ovarian cancer.

  • Community-based research to understand and reduce cancer disparities and lessen the burden of cancer in our entire region.

  • Improvements in colorectal cancer screening in urban and rural areas.

  • The use of cellular therapies and CAR-T cell therapy to treat blood and bone marrow cancers.

  • The development of novel immunotherapies for the prevention and treatment of cancer.

  • Community outreach and education, and enhanced access to cancer care.

  • The range of educational opportunities available at Siteman, from mentorships for high school and college students to advanced training for medical students and junior faculty.

Siteman was named Missouri’s only NCI-designated Cancer Center in 2001 and the state’s only Comprehensive Cancer Center in 2005. Today, Siteman treats more than 75,000 unique patients, including 12,000 newly diagnosed patients, every year.

Table of Contents

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login